Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: High dose of telmisartan
Drug: Low dose of telmisartan
Drug: HCTZ

First Posted Date: 2014-10-13

Last Posted Date: 2023-12-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02262780

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan
Drug: Telmisartan/HCTZ fixed combination
Drug: Hydrochlorthiazide (HCTZ)

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02262624

Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)

Completed

Conditions: Hypertension

Interventions: Drug: Micardis®
Drug: MicardisPlus®

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 266

Registration Number: NCT02262611

Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pramipexole ER tablets
Drug: Pramipexole IR tablets
Drug: Placebo matching Pramipexole IR tablets
Drug: Placebo matching Pramipexole ER tablets
Other: Standard high-fat breakfast

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT02261103

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pramipexole immediate release (IR) tablets

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02261090

Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Candesartan
Drug: Placebo
Drug: Telmisartan

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02261116

Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan/Amlodipine low dose
Drug: Telmisartan/Amlodipine high dose
Other: Japanese meal

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02261064

Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Hyoscine butylbromide

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02261077

Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan film-coated tablet
Drug: Telmisartan uncoated tablet

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02261129

Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: KUC 7483 CL
Drug: Placebo

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 35

Registration Number: NCT02259933

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy